Thioureidobutyronitrile

Drug Profile

Thioureidobutyronitrile

Alternative Names: Kevetrin

Latest Information Update: 22 Jun 2017

Price : $50

At a glance

  • Originator Cellceutix
  • Developer Innovation Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Nitriles; Small molecules
  • Mechanism of Action Alkylating agents; Apoptosis stimulants; Caspase 3 stimulants; Poly(ADP-ribose) polymerase modulators; Retinoblastoma protein modulators; Tumour suppressor protein p53 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinoblastoma; Pancreatic cancer; Ovarian cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes - Ovarian cancer

Highest Development Phases

  • Phase II Ovarian cancer
  • Phase I Solid tumours
  • Preclinical Acute myeloid leukaemia; Breast cancer; Chronic myeloid leukaemia; Colorectal cancer; Glioblastoma; Head and neck cancer; Lung cancer; Lymphoma; Multiple myeloma; Pancreatic cancer; Prostate cancer; Renal cancer; Retinoblastoma

Most Recent Events

  • 07 Jun 2017 Cellceutix is now called Innovation Pharmaceuticals
  • 30 May 2017 Preclinical trials in Acute myeloid leukaemia in USA (IV)
  • 30 May 2017 Pharmacodynamics data from preclinical study in Acute myeloid leukaemia released by Cellceutix
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top